MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.

Time frame: Baseline through 5 years

Phase 1a: Number of Participants with DLT

Time frame: During the first 28-day cycle of LY3962673 treatment

Phase 1a: Number of Participants with DLT Equivalent Toxicities

Time frame: During the first 28-day cycle of LY3962673 treatment

Phase 1b: Overall Response Rate (ORR)

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Time frame: Up to approximately 5 years

Phase 1b: Best Overall Response (BOR)

BOR per investigator assessed RECIST 1.1

Time frame: Up to approximately 5 years

Phase 1b: Duration of Response (DOR)

DOR per investigator assessed RECIST 1.1

Time frame: Up to approximately 5 years

Phase 1b: Time to Response (TTR)

TTR per investigator assessed RECIST 1.1

Time frame: Up to approximately 5 years

Phase 1b: Disease Control Rate (DCR)

DCR per investigator assessed RECIST 1.1

Time frame: Up to approximately 5 years